Alpha 2.0
Login Register
» Authors » Paul Chindemi

Paul Chindemi

Explore the profile of Paul Chindemi including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 6
Citations 91
Followers 0
Related Specialties
Biochemistry
Hematology
Cardiology & Vascular Diseases
Top 10 Co-Authors
Jeffrey I Weitz
Anthony K C Chan
Denise M Foulon
Leslie R Berry
Thomas J Podor
Paul J Berti
David H Farrell
Murray S Junop
Richard Austin
Stephanie Campbell
Published In
J Biol Chem
Biochemistry
Thromb Haemost
J Biochem
Affiliations
Soon will be listed here.
Recent Articles
1.
Evidence of kinetic control of ligand binding and staged product release in MurA (enolpyruvyl UDP-GlcNAc synthase)-catalyzed reactions
Jackson S, Zhang F, Chindemi P, Junop M, Berti P
Biochemistry . 2009 Nov; 48(49):11715-23. PMID: 19899805
MurA (enolpyruvyl UDP-GlcNAc synthase) catalyzes the first committed step in peptidoglycan biosynthesis. In this study, MurA-catalyzed breakdown of its tetrahedral intermediate (THI), with a k(cat)/K(M) of 520 M(-1) s(-1), was...
2.
Catalytic residues and an electrostatic sandwich that promote enolpyruvyl shikimate 3-phosphate synthase (AroA) catalysis
Berti P, Chindemi P
Biochemistry . 2009 Mar; 48(17):3699-707. PMID: 19271774
Enolpyruvylshikimate 3-phosphate synthase (EPSP synthase, AroA) catalyzes the sixth step in aromatic amino acid biosynthesis. It forms EPSP from shikimate 3-phosphate (S3P) and phosphoenolpyruvate (PEP) in an addition/elimination reaction that...
3.
Structural effects of a covalent linkage between antithrombin and heparin: covalent N-terminus attachment of heparin enhances the maintenance of antithrombin's activated state
Mewhort-Buist T, Junop M, Berry L, Chindemi P, Chan A
J Biochem . 2006 Sep; 140(2):175-84. PMID: 16954536
We have produced a molecule comprising of permanently-activated covalently linked antithrombin and heparin (ATH). This study was designed to elucidate the covalent linkage point(s) for heparin on antithrombin and conformational...
4.
Binding of heparin to plasma proteins and endothelial surfaces is inhibited by covalent linkage to antithrombin
Chan A, Paredes N, Thong B, Chindemi P, Paes B, Berry L, et al.
Thromb Haemost . 2004 Apr; 91(5):1009-18. PMID: 15116263
Unfractionated heparin (UFH) and low molecular weight heparin (LMWH) are used for prophylaxis and treatment of thrombosis. However, UFH has a short plasma half-life and variable anticoagulant response in vivo...
5.
Incorporation of vitronectin into fibrin clots. Evidence for a binding interaction between vitronectin and gamma A/gamma' fibrinogen
Podor T, Campbell S, Chindemi P, Foulon D, Farrell D, Walton P, et al.
J Biol Chem . 2001 Dec; 277(9):7520-8. PMID: 11744726
Vitronectin is an abundant plasma protein that regulates coagulation, fibrinolysis, complement activation, and cell adhesion. Recently, we demonstrated that plasma vitronectin inhibits fibrinolysis by mediating the interaction of type 1...
6.
Vimentin exposed on activated platelets and platelet microparticles localizes vitronectin and plasminogen activator inhibitor complexes on their surface
Podor T, Singh D, Chindemi P, Foulon D, McKelvie R, Weitz J, et al.
J Biol Chem . 2001 Dec; 277(9):7529-39. PMID: 11744725
Type 1 plasminogen activator inhibitor (PAI-1), the primary inhibitor of tissue-type plasminogen activator (t-PA), is found in plasma and platelets. PAI-1 circulates in complex with vitronectin (Vn), an interaction that...